June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
April 2010 in “Nature Reviews Urology” 1 citations
,
November 2025 in “International Journal of Clinical Pharmacy” Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
3 citations
,
May 2019 in “Cytotherapy” ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
22 citations
,
March 2017 in “Journal of the Formosan Medical Association” The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
Trichoriboside treatment helps maintain scalp hair by increasing cAMP levels in hair follicles of men with hair loss.
2 citations
,
January 2018 in “Elsevier eBooks” Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
61 citations
,
September 2010 in “Fitoterapia” Extracts from Tridax procumbens L. have strong anti-inflammatory and antioxidant effects and block inflammation-causing enzymes.
January 2018 in “Journal of the American Academy of Dermatology” Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Sonidegib effectively treated basal cell carcinoma in a patient with lupus without worsening lupus symptoms.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
November 2024 in “Journal of Investigative Dermatology” Targeting PTEN can improve healing in venous leg ulcers.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet” October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
3 citations
,
October 2024 in “Frontiers in Pharmacology” Compounds from Pterocarpus indicus may help treat benign prostatic hyperplasia by stopping cell growth.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
9 citations
,
May 2022 in “Drugs in Context” Sonidegib effectively treated advanced basal cell carcinoma with mild side effects.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking TYK2 might be a new way to treat hair loss from alopecia areata.